BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 12838325)

  • 21. TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines.
    Yoshida S; Narita T; Koshida S; Ohta S; Takeuchi Y
    Pediatr Res; 2003 Nov; 54(5):709-17. PubMed ID: 12904602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells.
    Lippa MS; Strockbine LD; Le TT; Branstetter DG; Strathdee CA; Holland PM
    Apoptosis; 2007 Aug; 12(8):1465-78. PubMed ID: 17440816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.
    Frese S; Pirnia F; Miescher D; Krajewski S; Borner MM; Reed JC; Schmid RA
    Oncogene; 2003 Aug; 22(35):5427-35. PubMed ID: 12934102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
    Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
    J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
    Hermisson M; Weller M
    Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
    Liu X; Yue P; Khuri FR; Sun SY
    Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
    Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
    Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM
    Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.
    Van Geelen CM; de Vries EG; de Jong S
    Drug Resist Updat; 2004 Dec; 7(6):345-58. PubMed ID: 15790545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Role of caspase-8 and DR5 in TRAIL-induced apoptosis of neuroblastoma cells].
    Tong HX; Zhang JH; Ma L; Lu CW; Zhang JH
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Aug; 8(4):327-30. PubMed ID: 16923369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
    Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.
    Song JH; Song DK; Herlyn M; Petruk KC; Hao C
    Clin Cancer Res; 2003 Sep; 9(11):4255-66. PubMed ID: 14519653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins.
    Mirandola P; Sponzilli I; Gobbi G; Marmiroli S; Rinaldi L; Binazzi R; Piccari GG; Ramazzotti G; Gaboardi GC; Cocco L; Vitale M
    Int J Oncol; 2006 Jan; 28(1):127-33. PubMed ID: 16327988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay.
    Cillessen SA; Meijer CJ; Ossenkoppele GJ; Castricum KC; Westra AH; Niesten P; Muris JJ; Nijdam HF; van der Hem KG; Flens M; Hooijberg E; Oudejans JJ
    Br J Haematol; 2006 Aug; 134(3):283-93. PubMed ID: 16848771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
    Wahl H; Tan L; Griffith K; Choi M; Liu JR
    Gynecol Oncol; 2007 Apr; 105(1):104-12. PubMed ID: 17174384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Death to the bad guys: targeting cancer via Apo2L/TRAIL.
    Bouralexis S; Findlay DM; Evdokiou A
    Apoptosis; 2005 Jan; 10(1):35-51. PubMed ID: 15711921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone.
    Huang L; Xu J; Li K; Zheng MH; Kumta SM
    Bone; 2004 Jun; 34(6):971-81. PubMed ID: 15193543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas.
    Koornstra JJ; Kleibeuker JH; van Geelen CM; Rijcken FE; Hollema H; de Vries EG; de Jong S
    J Pathol; 2003 Jul; 200(3):327-35. PubMed ID: 12845629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.